These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27699717)

  • 1. MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.
    Yue F; Zeng S; Tang R; Tao G; Chan P
    Neurosci Bull; 2017 Feb; 33(1):17-27. PubMed ID: 27699717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
    Schneider JS; Pioli EY; Jianzhong Y; Li Q; Bezard E
    Mov Disord; 2013 May; 28(5):663-7. PubMed ID: 23238827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.
    Imbert C; Bezard E; Guitraud S; Boraud T; Gross CE
    J Neurosci Methods; 2000 Mar; 96(1):71-6. PubMed ID: 10704673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
    Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
    Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys.
    Galvan A; Devergnas A; Pittard D; Masilamoni G; Vuong J; Daniels JS; Morrison RD; Lindsley CW; Wichmann T
    ACS Chem Neurosci; 2016 Nov; 7(11):1543-1551. PubMed ID: 27596273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel gripping test for the evaluation of the finger fine motor ability in MPTP-treated monkeys.
    Kobayashi S; Asakawa T; Nozaki T; Sugiyama K; Sameshima T; Kurozumi K
    J Integr Neurosci; 2020 Jun; 19(2):209-215. PubMed ID: 32706185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys.
    Doan VD; Grondin R; Hadj Tahar A; Grégoire L; Bédard PJ
    Clin Neuropharmacol; 1999; 22(5):281-7. PubMed ID: 10516879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Samadi P; Grégoire L; Rassoulpour A; Guidetti P; Izzo E; Schwarcz R; Bédard PJ
    Mov Disord; 2005 Jul; 20(7):792-802. PubMed ID: 15954116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy.
    Jourdain VA; Grégoire L; Morissette M; Morin N; Parent M; Di Paolo T
    J Neurosurg; 2013 Jan; 118(1):180-91. PubMed ID: 23082890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Moore C; Meshul CK
    Neuroscience; 2015 Apr; 290():454-71. PubMed ID: 25655214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
    Johnston TH; van der Meij A; Brotchie JM; Fox SH
    Mov Disord; 2010 Jul; 25(10):1379-90. PubMed ID: 20310030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
    Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.
    Potts LF; Wu H; Singh A; Marcilla I; Luquin MR; Papa SM
    Exp Neurol; 2014 Jun; 256():133-43. PubMed ID: 24070854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
    Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
    Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.